Research into direct-to-consumer (DTC) genetic tests, conducted at the Department of Ophthalmology, Erasmus Medical Center, Rotterdam, has concluded that while most of the commercial tests evaluated are accurate at genotyping, they are not accurate at risk prediction and their inaccuracy appears to arise from the methodology used. The Dutch study assessed the outputs of four direct-to-consumer genetic testing companies (23andMe, deCodeme, Easy DNA and Genetic Testing Laboratories) for their results regarding AMD on samples provided by three of the study’s authors. The study concluded that direct-to-consumer personal genome tests are not currently suitable for clinical application and that more comprehensive genetic testing and the inclusion of environmental risk factors into the tests on offer may improve the quality of risk prediction for AMD in the future.